Providing your location allows us to show you nearby locations and doctors.
Clinical Trials
Clinical trials are carefully designed research studies that explore how new treatments or medical approaches work for specific conditions and people. These studies are guided by strict safety and ethical guidelines to protect those who take part and to make sure the information collected is accurate. Clinical trials are an important part of the medical discovery process, helping turn early research into real-world care. By participating, individuals can access potential new therapies and contribute to improving healthcare for future patients.
Joining a Clinical Trial at Nuvance Health
The care team talks with you about any clinical trials for which you may be eligible. We explain what to expect from a clinical trial, so you can decide if taking part in one is right for you.
To inquire if you're eligible for a clinical trial, contact: [email protected] or call (203) 739-4551.
Cardiology
Arrhythmia
Product Surveillance Registry Platform
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Sankar Varanasi, MD
Lead coordinator: Rishitha Thankionda
Contact email: [email protected]
Contact phone: (845) 790-5844
Librexia AF
An orally administered anticoagulant for the potential prevention and/or treatment of atherothrombotic and thromboembolic events associated with atrial fibrillation.
Locations:
The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Danbury Hospital, 24 Hospital Avenue, Danbury, CT 06810
Principal investigator NY: M. Zubair Jafar, MD
Lead coordinator CT: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
Principal investigator CT: Carol Gemayel-Barra, MD
Lead coordinator CT: Dawn Marie Morsey
Contact email: [email protected]
Contact phone: (203) 739-4551
Preference Survey Study
This non-interventional study will collect data on preferences of physicians that treat Atrial Fibrillation (AF) and of patients that live with AF in the US.
Locations:
The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Danbury Hospital, 24 Hospital Avenue, Danbury, CT 06810
Principal investigator NY: M. Zubair Jafar, MD
Lead coordinator CT: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
Principal investigator CT: Carol Gemayel-Barra, MD
Lead coordinator CT: Dawn Marie Morsey
Contact email: [email protected]
Contact phone: (203) 739-4551
Real AF
The objective of this registry is to assess clinical outcomes of Radiofrequency ablations in the treatment of patients with Paroxysmal or Persistent atrial fibrillation.
Principal investigator: David Steckman, MD
Lead coordinator: Olatunde Olayini
Contact email: [email protected]
Contact phone: (845) 790-5844
Coronary Disease
DAL-302 (dal-GenE-2)
A study to evaluate the effects of Dalcetrapib on cardiovascular (CV) risk in patients who had a recent Acute Coronary Syndrome (ACS).
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
The purpose of this study is to evaluate methods of reducing the risk of major cardiovascular events in adults.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Sunny Intwala, MD
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
Heart Failure
ALLEVIATE
This study is evaluating a heart monitoring technology that may provide early detection of heart failure events. The study will utilize the Reveal LINQ Insertable Cardiac Monitor (ICM) with an investigational ALLEVIATE-HF RAMware download for collection of sensor data will be monitored.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Sankar Varanasi, MD
Lead coordinator: Preethi Gopalaiah
Contact email: [email protected]
Contact phone: (845) 790-5844
DAPA ACT HF/TIMI 68
This study is following patients who have been stabilized during hospitalization for acute heart failure.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: James Lyons, MD
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
EMPOWER (FKA CARILLON)
The objective of this study is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Rajeev Narayan, MD
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
Drain HF
This study is evaluating the safety and effectiveness of the Aortix System versus standard of care medical therapy in patients hospitalized with acute decompensated heart failure (ADHF) and persistent congestion despite usual medical management.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigators: James Lyons, MD / Rajeev Narayan, MD
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
AIM HIGHer
The overall objective of the AIM HIGHer Clinical Trial is to determine whether cardiac contractility modulation (CCM) therapy delivered by an implantable device (Optimizer System), can improve outcomes in patients with heart failure.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Sankar Varanasi, MD
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
Contemp-ICD
The objective of this study is to compare patients with a Non-implantable carioverter defibrillator (ICD) vs ICD management in patients with heart failure.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Sankar Varanasi, MD
Lead coordinator: Rishitha Thanikonda
Contact email: [email protected]
Contact phone: (845) 790-5844
Myocardial Infarction
Evolve MI
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Louis Kantaros, MD
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
Artemis
The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when started as early as possible in adult patients with myocardial infarction (heart attack).
Location: Danbury Hospital, 24 Hospital Avenue, Danbury, CT 06810
Principal investigator:Hal Wasserman, MD
Lead coordinator: Danielle Souza
Contact email: [email protected]
Contact phone: (203) 739-4551
Vesalius CV
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events.
Location: The Heart Center, 1 Columbia Street, Poughkeepsie, NY 12601
Principal investigator: Louis Kantaros, MD
Lead coordinator: Tricia Landi
Contact email: [email protected]
Contact phone: (845) 790-5844
Gastroenterology
Crohn's Disease
Affirm (M23-784)
This is a clinical study to evaluate the efficacy and safety of Risankizumab subcutaneous induction treatment in subjects with moderately to severely active Crohn's Disease.
Location: 24 Hospital Avenue, Danbury, CT 06810
Principal investigator: Adam Gorelick, MD
Lead coordinator: Danielle Souza
Contact email: [email protected]
Contact phone: (203) 739-4551
Target-CD (M24-885)
M24-885 is an open-label clinical study to evaluate the clinical efficacy and safety of targeted therapies (TaTs) in moderate to severe Crohn’s Disease.
Location: 24 Hospital Avenue, Danbury, CT 06810
Principal investigator: Adam Gorelick, MD
Lead coordinator: Danielle Souza
Contact email: [email protected]
Contact phone: (203) 739-4551
Ulcerative Colitis
Abtect-2
The purpose of this trial is to evaluate study medication vs placebo in inducing clinical remission in patients with moderately to severely active ulcerative colitis.
Location: 24 Hospital Avenue, Danbury, CT 06810
Principal investigator: Adam Gorelick, MD
Lead coordinator: Danielle Souza
Contact email: [email protected]
Contact phone: (203) 739-4551
Abtect
This study is the maintenance phase for participants who have completed either one of the following induction studies ABX464-105 and abx464-106.
Location: 24 Hospital Avenue, Danbury, CT 06810
Principal investigator: Adam Gorelick, MD
Lead coordinator: Danielle Souza
Contact email: [email protected]
Contact phone: (203) 739-4551
Infectious Disease
Human Non-Variola Orthopoxvirus Infections
TPOXX-EAP
Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children
Locations:
24 Hospital Avenue, Danbury, CT 06810
45 Reade Place, Poughkeepsie, NY 12601
34 Maple Street, Norwalk, CT 06856
Principal Investigators:
Contact email: [email protected]
Contact phone: (203) 739-4551
Neurology
Migraine
C-BEOND
The purpose of this study is to evaluate the efficacy of Dysport injection compared to placebo in reducing monthly migraine days in adult participants.
Location: 21 Reade Place, Poughkeepsie, NY 12601
Principal investigator: Hida Nierenburg, MD
Lead coordinator: Preethi Gopalaiah
Contact email: [email protected]
Contact phone: (845) 790-5844E-BEOND
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® injection when compared with placebo in preventing episodic migraine.
Location: 21 Reade Place, Poughkeepsie, NY 12601
Principal investigator: Hida Nierenburg, MD
Lead coordinator: Preethi Gopalaiah
Contact email: [email protected]
Contact phone: (845) 790-5844
Multiple Sclerosis
Verismo
The objective is to assess the incidences and outcomes of breast cancer patients with multiple sclerosis newly exposed to ocrelizumab under routine clinical care
Location: 79 Sand Pit Road, Suite 301, Danbury, CT 06810
Principal investigator: David Greco, MD
Lead coordinator: Dawn Marie Morsey
Contact email: [email protected]
Contact phone: (203) 739-4551
Stroke
OCEANIC STROKE
Study to investigate the efficacy and safety of Asundexian compared with placebo in participants after an acute non-cardioembolic ischemic stroke or high-risk TIA.
Location: 21 Reade Place, Poughkeepsie, NY 12601
Principal investigator: Paul Wright, MD
Lead coordinator: Preethi Gopalaiah
Contact email: [email protected]
Contact phone: (845) 790-5844
The Anticoagulation in Intracerebral Hemorrhage Survivors for Stroke Prevention and Recovery (ASPIRE) study is looking to determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent Intracerebral hemorrhage (ICH) and atrial fibrillation (AF).
Locations:
21 Reade Place, Poughkeepsie, NY 12601
79 Sand Pit Road, Suite 301, Danbury, CT 06810
Principal investigator NY: Paul Wright, MD
Lead coordinator: Preethi Gopalaiah
Contact email: [email protected]
Contact phone: (845) 790-5844
Principal investigator CT: Charles Guardia, MD
Lead coordinator: Dawn Marie Morsey
Contact email: [email protected]
Contact phone: (845) 790-5844
The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS).
Location: 21 Reade Place, Poughkeepsie, NY 12601
Principal investigator: Paul Wright, MD
Lead coordinator: Preethi Gopalaiah
Contact email: [email protected]
Contact phone: (845) 790-5844
Pharmacy
PharmacyKeeper
MMS-22MK-001 (PharmacyKeeper)
Study to Assess the Impact of the PharmacyKeeperTM Suite of Solutions on Sterile Compounding Safety, Efficiency, and Compliance
Location: 24 Hospital Avenue, Danbury, CT 06810
Principal investigator: Samuel Strong
Lead coordinator: Dawn Marie Morsey
Contact email: [email protected]
Contact phone: (203) 739-4551
Pulmonary
Alpha-1 Antitrypsin Deficiency (AATD)
INBRX101-01-201
Alpha-1 Antitrypsin Deficiency (AATD) is a chronic, genetic disorder that can affect multiple organ systems but is most prominently associated with causing lung disease and progressive pulmonary deteriorations. The study medication poses characteristics and features that may address an important existing unmet medical need for the treatment of AATD emphysema.
Location: 33 Germantown Road, Danbury, CT 06810
Principal investigator: Douglas Kahn, DO
Lead coordinator: Margaret Mukwaya
Contact email: [email protected]
Contact phone: (203) 739-4551
INBRX101-01-202
This is an open label extensions study to INBRX101-01-201 to evaluate the long-term safety and tolerability of SAR447537
Location: 33 Germantown Road, Danbury, CT 06810
Principal investigator: Douglas Kahn, DO
Lead coordinator: Margaret Mukwaya
Contact email: [email protected]
Contact phone: (203) 739-4551
TDN-001
Rare diseases, such as AATD, typically affect a relatively small population making the disease challenging to prevent, treat or cure. One of the largest obstacles in AATD research remains finding sufficient numbers of volunteers to participate in research studies. The Alpha-1 Foundation Therapeutic Development Network (TDN) will facilitate the design and execution of clinical trials to improve the care of patients with AATD.
Location: 33 Germantown Road, Danbury, CT 06810
Principal investigator: Douglas Kahn, DO
Lead coordinator: Margaret Mukwaya
Contact email: [email protected]
Contact phone: (203) 739-4551
Chronic Obstructive Pulmonary Disease (COPD)
LunAIRo
The purpose of this study is to demonstrate the efficacy of CHF 5993 to improve pre-dose lung function compared with CHF 1535 in subjects with COPD
Location: 520 West Avenue, Norwalk, CT 06850
Principal investigator: Ian Weir, DO
Lead coordinator: Margaret Mukwaya
Contact email: [email protected]
Contact phone: (203) 739-4551
Surgery
Soft Tissue Reconstruction
Myriad Registry
The purpose of the post-market observational clinical investigation is to assess the safety and efficacy of Matrix and Morcells across a range of soft tissue reconstruction procedures.
Location: 21 Reade Place, Poughkeepsie, NY 12601
Principal investigators:
Lead coordinator: Olatunde Olaniyi
Contact email: [email protected]
Contact phone: (845) 790-5844